Rich Duprey

Rich Duprey

InvestorPlace Contributor

After two decades of patrolling the dark corners of suburbia as a police officer, Rich Duprey hung up his badge and gun to begin writing full time about stocks and investing. For the past 20 years he’s been cruising the markets looking for companies to lock up as long-term holdings in a portfolio while writing extensively on the broad sectors of consumer goods, technology, and industrials.

Because his experience isn’t from the typical financial analyst track, Rich is able to break down complex topics into understandable and useful action points for the average investor. His writings have appeared on Yahoo! Finance, Nasdaq.com, and The Motley Fool, while he has been interviewed for both U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, The Boston Globe, Milwaukee Journal Sentinel, Danbury Register, The News-Times, South Florida Sun Sentinel, Cheddar News, Guns.com, L’Express, KERA News, WUTR, and Insight Magazine.

Recent Articles

3 Blue-Chip Stocks to Buy If the Dow Crashes

By Rich Duprey, InvestorPlace Contributor

Blue-chip stocks provide the ballast to keep a portfolio steady when markets go south as they offer reliable long-term returns.

3 Growth Stocks Under $5 to Buy Today

By Rich Duprey, InvestorPlace Contributor

Growth stocks at a cheap price in a bull market tend to be rare but offer outsized potential when they are discovered.

2 Stocks Nancy Pelosi Just Bought, and 1 She Sold. Should You Follow Pelosi’s Trades?

By Rich Duprey, InvestorPlace Contributor

Politicians insist they are not trading on inside information, but these Nancy Pelosi stock trades might suggest otherwise.

ChargePoint Stock Is the Hidden Gem in the EV Sector’s Turnaround

By Rich Duprey, InvestorPlace Contributor

ChargePoint stock has lost nearly three-quarters of its value but a renewed focus on growing profitably could change that direction quickly.

Alnylam Stock Is a Blockbuster Biopharma In the Making

By Rich Duprey, InvestorPlace Contributor

Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market.

Load More